



HAL
open science

Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications

Menéndez-González Manuel, Bogdan-Ionel Tamba, Maxime Leclere, Mostafa Mabrouk, Thomas-Gabriel Schreiner, Romeo Ciobanu, Tomás-Zapico Cristina

► **To cite this version:**

Menéndez-González Manuel, Bogdan-Ionel Tamba, Maxime Leclere, Mostafa Mabrouk, Thomas-Gabriel Schreiner, et al.. Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications. *Pharmaceutics*, 2023, 15 (3), pp.768. 10.3390/pharmaceutics15030768 . hal-04096386

HAL Id: hal-04096386

<https://hal.umontpellier.fr/hal-04096386>

Submitted on 17 May 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Intrathecal pseudodelivery of drugs in the therapy of neurodegenerative diseases: rationale basis and potential applications

Menéndez-González Manuel^{1,2,3,*}, Bogdan Ionel Tamba⁴, Maxime Leclere⁵, Mostafa Mabrouk⁶, Thomas Gabriel Schreiner^{7,8,9}, Romeo Ciobanu⁹, Tomás-Zapico Cristina^{1,3}.

1. Facultad de Medicina y Ciencias de la Salud. Universidad de Oviedo, Calle Julián Clavería s/n 33006, Spain

2. Department of Neurology. Hospital Universitario Central de Asturias, Avenida Roma s/n, 33011, Oviedo, Spain

3. Instituto de Investigación Sanitaria del Principado de Asturias, Avenida Roma s/n, 33011, Oviedo, Spain

4. Advanced Research and Development Center for Experimental Medicine (CEMEX), "Grigore T. Popa" University of Medicine and Pharmacy, Universitatii Str., No. 16, 700155 Iasi, Romania

5. Institut Europeen des Membranes, Adaptative Supramolecular Nanosystems Group, University of Montpellier, ENSCM-CNRS, Place E. Bataillon CC047, 34095 Montpellier, France

6. Refractories, Ceramics and Building Materials Department, National Research Centre, 33El Bohouth St. (former EL Tahrir St.)-Dokki- Giza- Egypt P.O.12622

7. Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania

8. Department of Neurology, University of Medicine and Pharmacy "Gr. T. Popa", 700115 Iasi, Romania

9. Department of Electrical Measurements and Materials, Faculty of Electrical Engineering and Information Technology, Gheorghe Asachi Technical University of Iasi, 700050 Iasi, Romania

Abstract: Intrathecal pseudodelivery of drugs is a novel route to administer medications to treat neurodegenerative diseases based on the CSF-sink therapeutic strategy by means of implantable devices. While the development of this therapy is still in the preclinical stage, it offers promising advantages over traditional routes of drug delivery. In this paper, we describe the rationale basis of this system and provide a technical report on the mechanism of action, that relies on the use of nanoporous membranes enabling selective molecular permeability. On one side, the membranes do not permit the crossing of certain drugs; whereas, on the other side, they permit the crossing of target molecules present in the CSF. Target molecules, by binding drugs inside the system, are retained or cleaved and subsequently eliminated from the central nervous system. Finally, we provide a list of potential indications, the respective molecular targets, and the proposed therapeutic agents.

Keywords: drug delivery systems, intrathecal pseudodelivery, neurodegenerative diseases, intrathecal device, nanoporous membranes

1. The BBB, the CSF, and the neurodegenerative diseases

Neurodegenerative diseases (NDD) are a group of disorders of the central nervous system (CNS) that cause progressive death of nerve cells and loss of function in the brain and spinal cord. The CNS compartments are represented by the parenchyma of the brain and spinal cord, including the intracellular space with the intracellular fluids (ICF) and the extracellular space with the interstitial fluid (ISF), and the cerebrospinal fluid (CSF) space. The tissues of the CNS are separated from the systemic circulation by the blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) [1,2]. These barriers protect the CNS from endogenous and exogenous compounds present in the systemic circulation and are essential to ensure the proper function of the CNS. The BBB is a complex and highly selective structure, a veritable border for numerous substances (including macromolecules) found in the systemic circulation in their passage to the CNS [1]. This protective role is mainly the consequence of the presence of an endothelial layer with special features, with flattened, polarized endothelial cells that have an increased mitochondrial content, minimal pinocytic activity, a lack of fenestrations, and are closely linked via an elaborate protein network consisting of tight junctions and adherens junctions [2] (Figure 1A). Besides the almost inexistent paracellular passage of molecules, the presence of different highly selective transporters on endothelial cells limits the free entry of drugs toward the CNS [3]. Despite acting as a carrier by allowing the penetrance of glucose, vitamins, lipid-soluble molecules, and gases (carbon dioxide and oxygen) from the blood toward the CNS, the BBB serves as a shield against neurotoxins, but also for potentially therapeutic substances. Additionally, these physical-chemical properties of the BBB are maintained in physiological conditions grace to the intercellular crosstalk between endothelial cells and the other components of the BBB (pericytes, astrocytes, neurons). Regarding the BCSFB, it is located in the choroid plexus of the

brain ventricles, and it is composed of a cuboidal cell epithelium with adhering Kolmer cells, a highly vascularized stroma with connective tissue, and the brain capillary endothelium[4]. According to the classical paradigm, the primary role of the choroid plexus epithelial cells is the secretion of CSF into the brain ventricles, however, recent research acknowledges the protective role of the BCSFB for the cerebral parenchyma [5]. In contrast to the BCSFB and BBB, the CSF and the ISF are not tightly separated. Even large molecules up to the size of albumin can move passively from/to the ISF and the CSF. Circulation of CSF and ISF around and through the CNS transports not only fluids but also any solutes they carry, including nutrients, drugs, and metabolic wastes. Impairment of this circulation has profound implications for NDD[6].




Figure 1. 1A. The complex structure of the neurovascular unit in physiological conditions.

All components interact anatomically and chemically in a complex web to maintain its functions. Endothelial cells (purple), which make up the main part of the BBB, are characterized by high selectivity in transcellular transport, due to the tight junctions that fuse them together and restrict diffusion across the blood vessels. Pericytes (red) are essential cells in maintaining the structural and functional properties of the BBB and share a common basement membrane (blue) with endothelial cells. Astrocytes (yellow) are involved in supportive processes and have a strategic localization between neurons (green) and other components of the BBB, with their specialized end feet extending to the walls of the blood vessels. **1B. The most relevant pathophysiological changes of the neurovascular unit in NDD.** Many of the homeostatic processes of the BBB are impaired in NDD. Vascular integrity is impaired by damage to the endothelial cells (purple), which lose their impermeability in the tight junctions, along with atrophy of pericytes (red), astrocyte endfeet swelling (yellow), and collagen and laminin accumulation in the basal membrane (blue). Aggregates of protein builds up and organizes in plaques that surround the astrocytes and neurons. This causes neuroinflammation with the secretion of inflammatory cells and cytokines, with the central role played by microglia (dark blue). Within neurons (green), proteins may also accumulate in intracellular aggregates, which are associated with the accumulation of glial cells and neuronal dysfunction. Modified from Schreiner et al.[7] (Magda Pîrțac originally designed this figure by using Adobe Fresco).

Pathologically, besides cellular loss, most NDD exhibit molecular hallmarks such as beta-amyloid ($A\beta$), tau, α -synuclein, mSOD1, and TDP-43. Disease-distinctive proteins exist in different states that aggregate between them: soluble monomers aggregate together to form dimers and oligomers, that can form soluble protofibrils. In turn, protofibrils aggregate to form insoluble fibrils, that eventually deposit in the form of plaques or tangles [8]. Soluble proteins are present in the CSF, and in equilibrium -either direct or inverse, depending on the molecule and the stage of the disease- with the concentration in the ISF (Figure 1). Similarly, polyglutamine (polyQ) diseases are a group of genetic NDD caused by the abnormal expansion of a CAG trinucleotide repeat that is translated into an expanded polyQ sequence in the disease-causative proteins. The expanded polyQ sequence itself plays a critical disease-causative role in the pathogenic mechanisms underlying these diseases. The more general pathogenic mechanism in polyQ diseases is related to the fact that the expanded polyQ sequence promotes a conformational transition from the native monomer into the β -sheet-rich monomer, followed by the formation of soluble oligomers and finally insoluble aggregates with amyloid fibrillar structures (Figure 2). The intermediate soluble species including the β -sheet-rich monomer and oligomers exhibit substantial neurotoxicity [9].




Figure 2. Aggregation of proteins from monomers to plaques. Soluble monomers aggregate together to form dimers and oligomers, that can form soluble protofibrils. These protofibrils aggregate to form insoluble fibrils, that can form plaques. The process is dynamic and bidirectional, therefore complex aggregates can disaggregate into less complex aggregates. Modified from Kok et al, 2022[8].

From this perspective, the central event in the pathophysiology of NDD is a proteostasis imbalance leading to protein aggregation overwhelming the proteostasis capacity of brain cells (e.g., autophagy-lysosome and ubiquitin-proteasome systems), and interfering with the ability of neurons to cope with pathogenic proteins [10,11], which accumulate and deposit intracellularly and/or extracellularly (Figure 1B). Eventually, protein aggregates lead to neuronal cell death, frequently mediated by activated tyrosine kinases. Not in vain, the exquisitely tuned activity of protein kinases is essential to maintaining cellular homeostasis [12]. Whereas loss-of-function variants are generally associated with cancer, gain-of-function variants are associated with NDD. Since these pathways are crucial for degrading aggregate-prone proteins and dysfunctional organelles such as mitochondria, they help maintain cellular homeostasis. As post-mitotic neurons cannot dilute unwanted protein and organelle accumulation by cell division, the nervous system is particularly dependent on autophagic pathways. This dependence may be a vulnerability as people age and these processes become less effective in the brain. The origin of proteostasis imbalance may be due to a genetic origin and/or acquired causes. Today, the pathogenic mechanisms underlying most genetic NDD are generally known, yet we do not have a clear understanding of the etiologies of sporadic NDDs. In sporadic NDD, some risk or protective factors have been identified (genetic polymorphisms, style of life including exercise, sleep, and diet), but the precise links between these factors and the pathogenic mechanisms leading to proteostasis imbalance are yet to be deciphered. Anyway, the formation of aggregates of these proteins may be the consequence of different pathogenesis, including a variable combination of increased synthesis, synthesis of structurally abnormal forms, and decreased degradation, either by intracellular (autophagy, microglia) or extracellular systems [13–16]. A decrease in their clearance to compartments outside the brain parenchyma has been identified as a relevant contribution to protein accumulation in the CNS fluidic systems, due to the impairment of the BBB, the CSF flow, and the glymphatic system [17–23]. Protein degradation involves enzymes contributing to clear target molecules, such as neprilysin or insulysin, that clear A β [24]. The soluble fraction of the triggering receptor expressed on myeloid cells 2 (sTREM2) is a bioactive molecule capable of binding ligands, activating microglia, and regulating immune responses during neurodegenerative processes. While sTREM2 promotes microglial survival and stimulates the production of inflammatory cytokines depending, variants of sTREM2 are less potent in both suppressing apoptosis and triggering inflammatory responses. In Alzheimer's disease (AD), wild-type sTREM2 binds oligomeric A β and acts as an extracellular chaperone, blocking and reversing A β oligomerization and fibrillization, and preventing A β -induced neuronal loss *in vitro*. Levels of sTREM2 in CSF fall prior to AD clinical onset, rise in early AD, and fall again in late AD. Subjects with higher sTREM2 levels in CSF progress more slowly into and through AD than do subjects with lower sTREM2 levels, suggesting that sTREM2 may protect against AD [25–28].

In parallel to proteostasis disbalance, a common feature in NDD is chronic immune activation, in particular of astrocytes and microglia, the resident macrophages of the central nervous system [29]. CSF immune system dysregulates during healthy brain aging and especially during neurodegenerative processes. Monocytes upregulate lipid processing genes with age in cognitively normal CSF, particularly in neurodegeneration [30]. The release of aggregated pathogenic proteins such as A β , tau, α -synuclein, mSOD1, and TDP-43 into the extracellular space, drives the changes of microglia and astrocytes into their pro-inflammatory phenotypes (Figure 1B). The pro-inflammatory-phenotype astrocytes and activated microglia release pro-inflammatory factors, such as interleukins and tumor necrosis factor α (TNF- α), which act as mediators dysregulating the synaptic function, the BBB, the metabolic function, and CSF and

blood flow [5,29–34]. Altogether, the predominance of the pro-inflammatory state results in the increase of pro-inflammatory factors and in a decrease in the protein clearance; and ultimately in disease progression.

2. The problem of drug delivery to the CNS and its many explored solutions

The administration of drugs targeting the CNS poses challenges. The main difficulty is related to poor drug penetration through the BBB, as multiple *in vivo*, *in vitro*, and *in situ* experiments have demonstrated [35]. Small molecule diffusion through BBB operates in the same manner as solute-free diffusion through biological membranes. The probability of a given small molecule passing through the BBB can be predicted based on its molecular weight (MW) and structure. If the MW is greater than 450 Daltons, and/or the drug's structure includes polar functional groups that form more than seven hydrogen bonds, then its transport through the BBB will be low unless there is carrier-mediated transport [36]. Conversely, if the MW is less than 450 Daltons and the drug forms seven or fewer hydrogen bonds with water, then its transport through the BBB may be significant, provided that it is not a substrate for an active efflux transporter. In certain pathological conditions such as stroke or cancer, the BBB experiences structural and functional changes that damage the central nervous system. BBB leakage enables increased immune cell traffic and substance passage to the interstitial fluid. The BBB can be opened through physical interventions like hyperosmotic infusions or focused ultrasounds, which facilitates the entry of drugs such as mAbs [37,38]. When it comes NDD, BBB dysfunction is linked to chronic inflammation, heightened oxidative stress, and the pathological accumulation of misfolded proteins. These factors impede drug delivery to CNS in comparison to acute conditions. Furthermore, the BCSFB may also be altered in NDD, undergoing similar cellular and molecular changes to BBB alterations, leading to permeability changes[4].

In recent years, a multitude of brain drug delivery technologies emerged, including trans-cranial delivery, CSF delivery, BBB disruption, lipid carriers, prodrugs, stem cells, exosomes, nanoparticles, gene therapy, endogenous BBB carrier-mediated transport and receptor-mediated transport systems [36]. As presented in Figure 3, there are available at present both invasive and non-invasive techniques, while alternative routes shunting the natural brain barriers are also being explored. Nanoparticle (NP)-based systems have shown promising potential as precision medicines that can effectively penetrate the BBB by crossing, avoiding, or disrupting the BBB. Diverse systems, including liposomes, micelles, polymeric NPs, solid-lipid NPs, and inorganic NPs, have been investigated for NP drug loading to treat NDD[39,40]. Exosomes are extracellular vesicles secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Due to their natural origin and molecular similarities with most cell types, exosomes have emerged as promising therapeutic tools for numerous diseases, particularly NDD [41].




Figure 3: Current strategies/systems for drug delivery to the CNS. (Color code: blue – non-invasive methods, red – invasive methods, green – alternative methods; Abbreviations: BBB – blood-brain barrier; CNS – central nervous system; NP – nanoparticle).

166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206

Invasive techniques rely on implantable devices accessing the CSF -intrathecal (IT) or intraventricular (IVT)- or the ISF intraparenchymal delivery-. In contrast to the extensive use of the CSF for diagnostic purposes, the CSF has not been frequently regarded as a target biological fluid for therapies for CNS conditions because it requires invasive procedures and systems. Today, few drugs are delivered in the CSF, mainly because it is an invasive procedure not without risks. However, in the last decades, therapies addressed at the CSF have gained some momentum as a result of advanced treatments such as gene therapies and replacement enzymatic therapies which need IT or IVT delivery. While the IT drug delivery pathway is still regarded as an experimental approach in neurodegenerative diseases, this route has long been successfully used in the treatment of other pathological conditions and in the symptomatic therapy of pain and spasticity [42–45]. More recently, intrathecal infusion of Nusinersen, an antisense oligodeoxynucleotide (ASO), was approved by FDA and EMA for the treatment of spinal muscular atrophy (SMA) [46]. Several ASOs have been tested in clinical trials for their ability to treat brain or spinal cord parenchyma by injecting drugs into the lumbar CSF. One such ASO is Tominersen, which targets the huntingtin mRNA of Huntington's disease (HD). Another ASO, Tofersen, targets the superoxide dismutase 1 (SOD1) mRNA in SOD1-dependent amyotrophic lateral sclerosis (ALS). [47].

Controlled drug delivery systems (DDS) seek to improve patient compliance by increasing therapeutic efficacy, extending drug release time and stability, increasing drug bioavailability, reducing side effects, and reducing dosage frequency. Moreover, DDS contribute to the safety of pharmaceuticals during their whole delivery period by serving as various kinds of protective barriers that enclose them, minimizing the loss of active ingredients and any harmful impacts on patients. They are typically constructed at nanometric and micrometric levels in order to combine several qualities such as site-specificity, endurance, or external stimuli sensitivity[48–50].

Intrathecal pumps are a good example of implantable DDS targeting the CNS. Intrathecal pumps consist of an electromechanical pump cased with a metal reservoir that stores the medication, and an catheter that is implanted in the spinal intrathecal space to deliver the medication from the pump to the CSF, thus accessing the CNS where the medication takes effect. Two types of pumps are available: a constant rate pump delivers the medication at a constant rate, and a programmable pump delivers the medication according to a rate determined by a computer program[51,52]. While intrathecal pumps offer good control of the rate of drug release, and enable effective low dosing, thus reducing the incidence and severity of drug-derived adverse effects, they are not exempt from complications, including the risk of overdose as a result of incorrect pump programming, pump failure, CSF leak, granuloma formation, obstruction of CSF flow, and infections[53,54].

3. Clearing the CSF as a therapeutic strategy in neurodegenerative diseases

Different approaches have been investigated with the aim of removing pathogenic proteins from the CNS, including inhibition of protein synthesis, and promoting protein degradation. Most therapeutic strategies addressed to enhance the clearance of brain proteins rely on clearing them from the periphery [55]. Disease-modifying therapies, such as monoclonal antibodies (mAb) against target molecules, recently started showing clinical benefits in some NDD at last [56]. However, safety remains a concern, since peripherally administered mAbs may lead to serious side effects, such as immunologically mediated amyloid-related imaging abnormalities (ARIA) after anti-A β mAb therapies [57]. However, there might be a much more direct way of clearing proteins from the brain than removing them from the plasma: removing them from the CSF. This is the rationale of the so-called "CSF-sink therapeutic hypothesis" [58–60] (Figure 3).




Figure 4. Representation of 207

target molecule dynamics in four scenarios. From left to right: physiological condition (healthy subject), pathological 208
 (untreated neurodegenerative disease), and pathological treated with peripheral sink therapeutic approach and patho- 209
 logical treated with CSF-sink therapeutic approach. Red arrows represent spontaneous equilibrium of target molecules 210
 between CNS fluid compartments, green arrows represent pathways of therapeutic clearance of target molecules and 211
 orange arrows represent the secondary equilibrium of target molecules between CNS fluid compartments after therapy. 212
 Modified from Schreiner et al. [60]. 213
 214

Indeed, several attempts have been made to treat neurodegenerative diseases using different CSF filtration systems. In 215
 ALS, extracorporeal CSF filtration showed to successfully mitigate the neurotoxic capacity of CSF from subjects with 216
 sporadic Amyotrophic Lateral Sclerosis (ALS) *in vitro* [61] and in a mouse model [62]. However, a very small randomized, 217
 controlled, and open study in the nineties, concluded that filtration of 200-250 ml CSF daily, over five days, did 218
 not seem to have a substantial therapeutic effect in patients with ALS [63]. In a single case of familial ALS, there was 219
 subjective, but no objective, improvement of the patient immediately after CSF filtration and two weeks later [64]. 220
 It is worth revising methods aimed at CSF dilution or enhancing CSF flow, as they are closely related to CSF-sink ther- 221
 apeutic strategy. In AD, mechanical dilution of CSF has long been a proposed therapeutic approach [65]. CSF shunts 222
 such as ventriculo-peritoneal, ventriculo-pericardial, ventriculo-atrial and lumbo-peritoneal shunts are the recom- 223
 mended therapy for communicating hydrocephalus. Noteworthy, shunting procedures delay intracerebral deposition 224
 of A β in patients with communicating hydrocephalus [66]. COGNISHunt is a system for a continuous, low-flow ven- 225
 triculoperitoneal shunt (Eunoe, acquired by Integra Lifesciences). Results of the clinical trial showed that the difference 226
 between treatment groups, while still favoring the COGNISHunt group, was not statistically significant [67]. Arethusta 227
 (Leucadia Therapeutics) is a system based on an implantable device to restore CSF flow across the cribriform plate, with 228
 no clinical reports yet. 229

4. Intrathecal pseudodelivery of drugs: concept, advantages, and disadvantages 230

Therapeutics such as enzymes, antibodies, and even transport proteins (e.g., Albumin), which are mostly intended 231
 to link molecular targets to be removed from the organism, do not really need to be delivered in the fluid or tissue to 232
 action. In fact, binding to the molecular target can be achieved regardless of the compartment. With this in mind, IT 233
 pseudodelivery of drugs is a novel concept to administer drugs to treat CNS conditions relying on the CSF-sink ther- 234
 apeutic strategy [60], by means of implantable DDS to put in touch therapeutics with molecular targets inside of the 235
 device, without delivering to the biological fluid (hence the name “pseudo”-delivery). The key component in the device 236
 is a smart design of customized nanoporous membranes that allow the influx of small molecules (targets) at the time of 237
 preventing the efflux of therapeutics of larger molecular size (nanosieve). 238

Functional nanoporous materials are an important class of nanostructured materials because of their tunable poro- 239
 sity and pore geometry (size, shape, and distribution) and their unique chemical and physical properties. Progress in 240
 developing a broad spectrum of nanoporous materials has accelerated their use for extensive applications in biomedical 241
 fields [68]. Nanoporous membranes are natural or synthetic membranes that can be made from a variety of materials 242
 and can be fabricated in different configurations including pore size, surface coating, geometry, and pore distribution, 243

providing unique mass transport characteristics that have numerous potential biological and medical applications that involve isolating, sorting, sensing, and releasing biological molecules. Nanoporous membranes are of great interest in drug delivery because they offer a secure delivery system for medications and stop bodily enzymes from breaking them down and because they can be tailored-made and fine-tuned for precise control of the rate of drug delivery or to exquisitely adjust the selective molecular permeability [69] [70]. Nanoporous membranes can be used as stand-alone DDS or assembled into complex DDS. IT pseudodelivery is the first DDS to be endowed with nanoporous membranes acting on the CNS[71].

Devices for IT pseudodelivery of drugs look similar to intrathecal pumps as they also have a subcutaneous reservoir and an intrathecal catheter accessing the CSF. However, they are not necessarily endowed with electromechanical pumps. The mechanism of action depends on the use of nanoporous membranes enabling selective molecular permeability [71]. On one side, the membranes do not allow crossing drugs, but on the other side, they allow crossing the target molecules present in the CSF. Target molecules bind drugs inside the system, thus being trapped or cleaved and eliminated from the CNS (a short simulation illustrating the mechanism of action can be found as a supplemental file). Drugs are not released from the reservoir to the organism, and they can be replaced as needed percutaneously through self-sealing septa in the reservoir.

Not any target molecule or drug is suitable to be targeted/used via pseudodelivery. For a disease to be suitable to be treated using IT pseudodelivery, three conditions must be met:

1. A target molecule should be present in the CSF (soluble). This should be identified as potentially “toxic” or “pathogenic” and involved directly (aggregating proteins) or indirectly (mediators) in the physiopathology of the disease.
2. A drug acting specifically on the target molecule is needed. This can be an antibody, an aptamer, an enzyme, or any other compound that has specificity over the target molecule and either bind or cleave the target molecule.
3. A significant size difference should exist between the target and drug molecules. While other physicochemical features may also play a role (such as electrostatic charge), the size difference is the main feature driving the selective molecular permeability through nanoporous membranes.

While the development of this therapy is still in the preclinical stage, it offers promising advantages over traditional routes of delivery. Being target-selective provides advantages over other CSF clearance systems since the level of other proteins –not involved in disease pathogenesis– would be preserved. It also provides important advantages over “standard” peripherally administered drugs, including 1 acting continuously, on the CSF directly, is expected to be much more effective than acting peripherally; 2. immunoisolation of drugs impedes immune responses, fully avoiding immunologically mediated side effects reported with biological drugs systemically administered [72,73].

In contrast, potential adverse effects related to the intrathecal system implantation and functioning should be taken into consideration, with expected local complications similar to those seen with intrathecal pumps, such as CSF leak, hemorrhages, and infection, along with device-derived problems such as CSF flow obstruction or even device disconnection [72,73].

5. Potential applications of intrathecal pseudodelivery of drugs: diseases, targets, and relevant drugs

The field of disease-modifying therapies for NDD is one of the hottest topics in medicine nowadays. Despite a myriad of studies, no effective disease-modifying treatment is available at the present for most of these conditions [74] while the first disease-modifying therapies for AD have been recently approved with some controversy regarding their efficacy and safety [75,76]. However, much knowledge has been accumulated regarding the molecules and cellular pathways involved in the pathogenesis of NDD that can become valuable targets for future therapies. Different classes of therapeutics are suitable to be used via intrathecal pseudodelivery in the treatment of NDD. Table 1 summarizes the most relevant NDD, their known molecular targets, and the proposed therapeutic agents proposed to be applied through this route, based on previous evidence on the drugs’ mechanism of action. There is little research testing IT pseudodelivery in these conditions yet, hence this list should be considered just as therapeutic hypotheses today.

Table 1: Summary of the potential molecular targets and the proposed classes of therapeutic agents to be administered via IT pseudodelivery for the most relevant neurodegenerative diseases.

Neurodegenerative disease	Molecular target	Proposed classes of therapeutic agents
Alzheimer's disease	A β	mAbs, aptamers [72–78]
		Enzymes [24]
		Albumin [79,80]
		Protein conformation stabilizers and aggregation inhibitors [79–82]
	Tau protein	mAbs, aptamers [83,84]
		Protein conformation stabilizers and aggregation inhibitors [85,86]
sTREM2	mAbs, aptamers [87,88]	
IL-6	mAbs [89]	
TNF- α	fusion protein by recombinant DNA, mAb [90–93]	
Parkinson's disease and Dementia with Lewy bodies	α -synuclein	mAbs, aptamers [58,84,94,95]
		Enzymes [96]
		Protein conformation stabilizers and aggregation inhibitors [81,97]
	IL-6	mAbs [98]
	TNF- α	mAbs [99]
Multisystem Atrophy	α -synuclein	mAbs, aptamers [58,84,94,95]
		Protein conformation stabilizers and aggregation inhibitors [81,97]
		Enzymes [96]
Progressive supranuclear palsy	Tau	mAbs, aptamers [100,101]
		Protein conformation stabilizers and aggregation inhibitors [102]
	TDP43	mAbs, aptamers [103]

Frontotemporal dementia	Tau protein	mAbs, aptamers [83]
		Protein conformation stabilizers and aggregation inhibitors [102]
Amyotrophic lateral sclerosis	SOD	mAbs, aptamers [84]
		Protein conformation stabilizers and aggregation inhibitors [84,104,105]
	TDP43	mAbs, aptamers [106]
		Enzymes [107]
		Protein conformation stabilizers and aggregation inhibitors [108,109]
	Tau protein	mAbs, aptamers [83]
		Protein conformation stabilizers and aggregation inhibitors [102]
IL-6	mAbs [110]	
TNF- α	mAbs [111,112]	
Huntington's disease and other diseases caused by polynucleotide-mutated repeats	mutant HTT protein and other polyQ-mutated proteins	mAbs, aptamers [113]
		Protein conformation stabilizers and aggregation inhibitors [114,115]

Abbreviations: mAbs – monoclonal antibodies, SOD – superoxide dismutase, sTREM2 – soluble Triggering receptor expressed on myeloid cells 2, A β – beta-amyloid, TNF- α – tumor necrosis factor α , IL-6 – Interleukin 6.

Monoclonal antibodies (mAbs) directed against misfolded proteins such as A β , Tau protein, or α -synuclein are a first choice when considering IT pseudodelivery, as they demonstrated to be effective when administered intravenously in many studies [116]. Moreover, very recently mAbs targeting A β were approved for the treatment of AD in humans (see Aducanumab [77] and Lecanemab [75]). mAbs is the only class of therapeutics with in vivo studies published via intrathecal pseudodelivery, which showed feasibility, good safety, and histological efficacy in animal models of AD [72,73]. Aptamers are an interesting class of compound that could replace antibodies in the near future, as they can also be used for therapeutic purposes within the pseudodelivery device. Compared to currently available mAbs, aptamers have some advantages such as a smaller size and mass, lower immunogenicity, greater replicability, and a greater level of control (high durability, sensitivity, and specificity) [78]. Similarly, antibodies and aptamers binding other pathogenic proteins such as Alpha-syn, Tau, TDP43, or mutant HTT might be of interest to treat other NDD via pseudodelivery route, even if they failed when systemically administered for safety or efficacy reasons [58,83,84,94,95,101,103,113].

298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314

Other molecules binding pathogenic proteins can be of interest. For instance, human serum albumin (HSA) is a natural buffer of A β . A promising approach to AD prevention is to reduce the concentration of free A β by targeted stimulation of the interaction between HSA and A β . This approach can be implemented by pseudodelivering albumin alone [79] or in combination with agents increasing the affinity of HSA to A β through the action of HSA ligands [80].

Another therapeutic possibility is to act on the enzymatic dysfunction, a relevant example being the switch from the non-amyloidogenic pathway to the amyloidogenic one in AD [117]. In the same manner, compensating for the malfunctioning enzymes or even using different enzymes (from the family of membrane metallo-endopeptidase such as neprilysin and other A β cleaving enzymes [24]) inside the pseudodelivery device can be a smart option considering the high CSF throughput.

Protein conformation stabilization and aggregation inhibition that targets the upstream of the insoluble aggregate formation would be a promising approach toward the development of disease-modifying therapies for most NDD, particularly for polyQ diseases. PolyQ aggregation inhibitors of different chemical categories, such as intrabodies, peptides, and small chemical compounds, have been identified through intensive screening methods [114,115]. Among them, those with high molecular sizes are suitable to be used via IT pseudodelivery. The same approach could be used to inhibit the aggregation of A β , Tau, alpha-synuclein, SOD, and TDP43 [81,85,97,108,109,111,118]. In addition, clearing cofactors promoting protein aggregation, such as iron or tyrosine kinase, is an alternative way of inhibiting protein aggregation [119]. Interestingly, some nanomaterials such as polyoxometalates may also work as inhibitors of amyloid aggregation [82] and might be suitable to be used as therapeutic agents through this route.

Finally, another clear target in NDD are molecules involved in inflammation such as anti-TNF- α . According to several reports, anti-TNF- α agents may affect amyloidosis in inflammatory/autoimmune diseases, such as rheumatoid arthritis and familial Mediterranean fever [119]. Indeed, perispinal administration of the anti-TNF- α medication etanercept (a fusion protein produced by recombinant DNA) has been reported effective in cognitive improvement in one single case report [90], and similar results were obtained in animal studies [32]. Comparable results were noticed for infliximab, a chimeric monoclonal antibody already approved for the treatment of multiple autoimmune diseases such as Chron's disease, rheumatoid arthritis, and psoriasis. A study indicated that intracerebroventricular administration of infliximab reduced A β plaques and tau phosphorylation in APP/PS1 mice [91] and resulted in cognitive improvement in a human case [92], while recent research confirms the protective cerebral effects (reduced microgliosis, neuronal loss, and tau phosphorylation) of TNF- α inhibitors in a transgenic mouse model of tauopathy [112]. These results are encouraging, indicating that IT infliximab offers an alternative therapeutic approach for AD, and potentially for other neurodegenerative disorders whose pathogenesis involves TNF- α such as PD [99] and ALS [111]. Clinical trials for different conditions have shown a detrimental effect of TNF- α antagonists in advanced heart failure and anti-TNFs are associated with an increased risk of infection. Rare case reports of drug-induced lupus, seizure disorder, pancytopenia, and demyelinating diseases have been noted after systemic treatment with TNF- α antagonists [120,121]. Meanwhile, chronic dosing with a brain-penetrant biologic TNF-inhibitor induced hematology and iron dysregulation in aged APP/PS1 mice [93]. In this regard, IT pseudodelivery of anti-TNF- α agents may offer a safer route of administration.

Drugs targeting the complement component C5, CD19 on B cells, and the inter-leukin-6 (IL-6) receptor, have been used for the treatment of patients with refractory inflammatory CNS diseases. Particularly, Tocilizumab, a humanized, monoclonal antibody against the IL-6 receptor, has been tested for neurologic indications, such as neuromyelitis optica [122] or primary CNS vasculitis [123]. Tocilizumab has also been tested in ALS [110] and proposed in PD [98] and AD [89] (Elcioğlu et al., 2016). As IL-6 is present in the CSF, monoclonal antibodies binding IL-6 directly -such as HZ-0408b [124]- via IT pseudodelivery might be an alternative route to target inflammation in NDD.

Lastly, a TREM2-activating antibody with a BBB transport vehicle enhances microglial metabolism in AD models [87] and tau pathology and neurodegeneration are associated with an increase in CSF sTREM2 [88]. However, some of these experiments can be interpreted as full-length TREM2 protecting rather than sTREM2 [26]. Therefore, while sTREM2 might be a suitable target via IT pseudodelivery in AD, more knowledge is needed to understand how, when, and in what cases this target might be of interest.

6. Conclusions

IT pseudodelivery of drugs is a novel concept to administer drugs to treat NDD based on the CSF-sink therapeutic strategy by means of implanted devices. The mechanism of action relies on the properties of nanoporous membranes enabling selective molecular permeability.

Being an invasive procedure, the expected safety issues of IT pseudodelivery are related to device implantation and functioning. However, the promising advantages of IT pseudodelivery of drugs in terms of efficacy and drug-related safety would overcome the disadvantages.

Potentially, there are a number of NDD where IT pseudodelivery might be of interest. While there is a theoretical rationale supporting this indications, *in vitro* and *in vivo* testing is still lacking for most of them, therefore it should be considered just a therapeutic hypothesis today.

Author Contributions: All authors contributed to the writing of this manuscript.

Funding: The project “Nanoporous-Membranes for Intrathecal (Pseudo) Delivery of Drugs” received funding from Instituto de Salud Carlos III (ISCIII) (Project AC20/00017), Agence Nationale de la Recherche (ANR), Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii, and the Academy of Scientific Research and Technology (ASRT); under the umbrella of the ERA-NET EuroNanoMed.

Conflicts of Interest: The authors declare no conflict of interest.

References

- [1] Kadry H, Noorani B, Cucullo L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. *Fluids Barriers CNS*. 2020.
- [2] Katt ME, Xu ZS, Gerecht S, et al. Human brain microvascular endothelial cells derived from the BC1 iPS cell line exhibit a blood-brain barrier phenotype. *PLoS One*. 2016;11.
- [3] Alajangi HK, Kaur M, Sharma A, et al. Blood–brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders. *Mol Brain* [Internet]. 2022;15:49. Available from: <https://doi.org/10.1186/s13041-022-00937-4>.
- [4] Solár P, Zamani A, Kubíčková L, et al. Choroid plexus and the blood-cerebrospinal fluid barrier in disease. *Fluids Barriers CNS*. 2020.
- [5] Ayub M, Jin HK, Bae J sung. The blood cerebrospinal fluid barrier orchestrates immunosurveillance, immunoprotection, and immunopathology in the central nervous system. *BMB Rep*. 2021;54.
- [6] Kelley DH, Thomas JH. Cerebrospinal Fluid Flow. *Annu Rev Fluid Mech* [Internet]. 2023;55:237–264. Available from: <https://doi.org/10.1146/annurev-fluid-120720-011638>.
- [7] Schreiner TG, Creangă-Murariu I, Tamba BI, et al. In Vitro Modeling of the Blood–Brain Barrier for the Study of Physiological Conditions and Alzheimer’s Disease. *Biomolecules* [Internet]. 2022;12. Available from: <https://www.mdpi.com/2218-273X/12/8/1136>.
- [8] Kok FK, van Leerdam SL, de Lange ECM. Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer’s Disease Neuropathology. *Journal of Alzheimer’s Disease*. 2022.
- [9] Fan HC, Ho LI, Chi CS, et al. Polyglutamine (PolyQ) diseases: Genetics to treatments. *Cell Transplant*. 2014.
- [10] Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. *Lancet Neurology*. 2007. p. 352–361.
- [11] Nixon RA. The role of autophagy in neurodegenerative disease. *Nat Med*. 2013.
- [12] Schweig JE, Yao H, Beaulieu-Abdelahad D, et al. Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase. *Acta Neuropathol Commun*. 2017;5:69.
- [13] Huang Y, Happonen KE, Burrola PG, et al. Microglia use TAM receptors to detect and engulf amyloid β plaques. *Nat Immunol*. 2021;22.
- [14] Silvin A, Uderhardt S, Piot C, et al. Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration. *Immunity* [Internet]. 2022;55:1448–1465.e6. Available from: <https://doi.org/10.1016/j.immuni.2022.07.004>.
- [15] Lee J-H, Yang D-S, Goulbourne CN, et al. Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of A β in neurons, yielding senile plaques. *Nat Neurosci* [Internet]. 2022;25:688–701. Available from: <https://doi.org/10.1038/s41593-022-01084-8>.

-
- [16] Sikanyika NL, Parkington HC, Smith AI, et al. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease. *Neurochem Res.* 2019;44. 411
412
- [17] Elbert DL, Patterson BW, Lucey BP, et al. Importance of CSF-based A β clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways. *Commun Biol.* 2022;5. 413
414
- [18] Mestre H, Verma N, Greene TD, et al. Periarteriolar spaces modulate cerebrospinal fluid transport into brain and demonstrate altered morphology in aging and Alzheimer's disease. *Nat Commun [Internet].* 2022;13:3897. 415
416 Available from: <https://doi.org/10.1038/s41467-022-31257-9>. 417
- [19] Peng W, Achariyar TM, Li B, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. *Neurobiol Dis.* 2016;93. 418
419
- [20] da Mesquita S, Papadopoulos Z, Dykstra T, et al. Meningeal lymphatics affect microglia responses and anti-A β immunotherapy. *Nature.* 2021;593. 420
421
- [21] Li Y, Rusinek H, Butler T, et al. Decreased CSF clearance and increased brain amyloid in Alzheimer's disease. *Fluids Barriers CNS.* 2022;19. 422
423
- [22] Klostranec JM, Vucevic D, Bhatia KD, et al. Current concepts in intracranial interstitial fluid transport and the glymphatic system: Part i-anatomy and physiology. *Radiology.* 2021. 424
425
- [23] Lee MK, Cho SJ, Bae YJ, et al. MRI-Based Demonstration of the Normal Glymphatic System in a Human Population: A Systematic Review. *Front Neurol [Internet].* 2022;13. Available from: <https://www.frontiersin.org/articles/10.3389/fneur.2022.827398>. 426
427
- [24] Kato D, Takahashi Y, Iwata H, et al. Comparative studies for amyloid beta degradation: "Nepriylisin vs insulysin", "monomeric vs aggregate", and "whole A β 40 vs its peptide fragments." *Biochem Biophys Rep.* 2022;30. 429
430
- [25] Zhao A, Jiao Y, Ye G, et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease. *J Clin Invest [Internet].* 2022;132. Available from: <https://doi.org/10.1172/JCI158708>. 431
432
- [26] Brown GC, St George-Hyslop P. Does Soluble TREM2 Protect Against Alzheimer's Disease? *Front Aging Neurosci.* 2022. 433
434
- [27] Zhong L, Chen XF, Wang T, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. *Journal of Experimental Medicine.* 2017;214. 435
436
- [28] Yang J, Fu Z, Zhang X, et al. TREM2 ectodomain and its soluble form in Alzheimer's disease. *J Neuroinflammation.* 2020. 437
438
- [29] Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. *Transl Neurodegener.* 2020. 439
440
- [30] Piehl N, van Olst L, Ramakrishnan A, et al. Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment. *Cell [Internet].* 2022;185:5028-5039.e13. Available from: <https://www.sciencedirect.com/science/article/pii/S0092867422014635>. 441
442
- [31] Ng Kee Kwong KC, Gregory JM, Pal S, et al. Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: A systematic review of in vitro studies. *Brain Commun.* 2020. 444
445
- [32] Chang R, Yee K-L, Sumbria RK. Tumor necrosis factor α Inhibition for Alzheimer's Disease. *J Cent Nerv Syst Dis.* 2017;9. 446
447
- [33] Tortelli R, Zecca C, Piccininni M, et al. Plasma Inflammatory Cytokines Are Elevated in ALS. *Front Neurol.* 2020;11. 448
449
- [34] Sun Q, Huo Y, Bai J, et al. Inflammatory Cytokine Levels in Patients with Sporadic Amyotrophic Lateral Sclerosis. *Neurodegener Dis.* 2022;21. 450
451
- [35] Neumaier F, Zlatopolskiy BD, Neumaier B. Drug penetration into the central nervous system: Pharmacokinetic concepts and in vitro model systems. *Pharmaceutics.* 2021. 452
453

-
- [36] Pardridge WM. A Historical Review of Brain Drug Delivery. *Pharmaceutics* [Internet]. 2022;14. Available from: <https://www.mdpi.com/1999-4923/14/6/1283>. 454
455
- [37] Meng Y, Reilly RM, Pezo RC, et al. MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. *Sci Transl Med*. 2021;13. 456
457
- [38] Chu C, Jablonska A, Lesniak WG, et al. Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. *Journal of Controlled Release*. 2020;317. 458
459
- [39] Poudel P, Park S. Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems. *Pharmaceutics* [Internet]. 2022;14. Available from: <https://www.mdpi.com/1999-4923/14/4/835>. 460
461
462
- [40] Pinheiro RGR, Coutinho AJ, Pinheiro M, et al. Nanoparticles for targeted brain drug delivery: What do we know? *Int J Mol Sci*. 2021. 463
464
- [41] Cano A, Muñoz-Morales Á, Sánchez-López E, et al. Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges. *Pharmaceutics* [Internet]. 2023;15. Available from: <https://www.mdpi.com/1999-4923/15/1/298>. 465
466
467
- [42] Plassat R, Perrouin Verbe B, Menei P, et al. Treatment of spasticity with intrathecal baclofen administration: Long-term follow-up, review of 40 patients. *Spinal Cord*. 2004;42. 468
469
- [43] Koulousakis A. and Kuchta J. Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. In: Sakas Damianos E. and Simpson BA and KES, editor. *Operative Neuromodulation: Volume 1: Functional Neuroprosthetic Surgery An Introduction* [Internet]. Vienna: Springer Vienna; 2007. p. 181–184. Available from: https://doi.org/10.1007/978-3-211-33079-1_24. 470
471
472
473
- [44] de Andres J, Hayek S, Perruchoud C, et al. Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient. *Frontiers in Pain Research* [Internet]. 2022;3. Available from: <https://www.frontiersin.org/articles/10.3389/fpain.2022.900566>. 474
475
476
- [45] Pope JE, Deer TR, Bruel BM, et al. Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm. *Pain Practice*. 2016. 477
478
- [46] Aartsma-Rus A. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. *Nucleic Acid Ther*. 2017. 479
480
- [47] Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. *Nat Nanotechnol*. 2021. 481
482
- [48] Adepu S, Ramakrishna S. Controlled drug delivery systems: Current status and future directions. *Molecules*. 2021. 483
484
- [49] Rafiee MH, Rasool BKA. An Overview of Microparticulate Drug Delivery System and its Extensive Therapeutic Applications in Diabetes. *Adv Pharm Bull*. 2022. 485
486
- [50] Nunes D, Loureiro JA, Pereira MC. Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer's Drugs. *Pharmaceutics* [Internet]. 2022;14. Available from: <https://www.mdpi.com/1999-4923/14/11/2296>. 487
488
489
- [51] Ericson T, Singla P, Kohan L. Intrathecal Pumps. *Physical Medicine and Rehabilitation Clinics* [Internet]. 2022;33:409–424. Available from: <https://doi.org/10.1016/j.pmr.2022.01.004>. 490
491
- [52] Peck D, Diwan S. Programmable versus Fixed-Rate Pumps for Intrathecal Drug Delivery. *Intrathecal Drug Delivery for Pain and Spasticity*. 2011;84–89. 492
493
- [53] Delhaas EM, Huygen FJPM. Complications associated with intrathecal drug delivery systems. *BJA Educ* [Internet]. 2020;20:51–57. Available from: <https://doi.org/10.1016/j.bjae.2019.11.002>. 494
495
- [54] Gevirtz C. Complications Associated With Intrathecal Pumps. *Topics in Pain Management*. 2012;27. 496

-
- [55] Zhang Y, Lee DHS. Sink hypothesis and therapeutic strategies for attenuating A β levels. *Neuroscientist*. 2011;17. 497
- [56] Lacorte E, Ancidoni A, Zaccaria V, et al. Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials. *Journal of Alzheimer's Disease*. 2022. 498-500
- [57] Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. 1:3. Available from: <https://doi.org/10.1007/s13311-022-01308-6>. 501-503
- [58] Menéndez-González M, Padilla-Zambrano HS, Tomás-Zapico C, et al. Clearing extracellular alpha-synuclein from cerebrospinal fluid: A new therapeutic strategy in parkinson's disease. *Brain Sci*. 2018;8. 504-505
- [59] Menendez-Gonzalez M, Padilla-Zambrano HS, Alvarez G, et al. Targeting beta-amyloid at the CSF: A new therapeutic strategy in Alzheimer's disease. *Front Aging Neurosci*. 2018;10. 506-507
- [60] Schreiner TG, Menéndez-González M, Popescu BO. The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease-From Theory to Design of Applied Systems. 2022; Available from: <https://creativecommons.org/licenses/by/4.0/>. 508-510
- [61] Gao I, Griffin R, Celestin N, et al. Filtration attenuates sporadic ALS CSF-induced motor neuron death in vitro (P1-13.007). *Neurology [Internet]*. 2022;98:2154. Available from: http://n.neurology.org/content/98/18_Supplement/2154.abstract. 511-513
- [62] Celestin N, Shue T, Beaty J, et al. Filtration reduces neurotoxicity of sporadic ALS cerebrospinal fluid in a mouse model (2264). *Neurology [Internet]*. 2021;96:2264. Available from: http://n.neurology.org/content/96/15_Supplement/2264.abstract. 514-516
- [63] Finsterer J, Mamoli B. Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. *Eur J Neurol*. 1999;6. 517
- [64] Finsterer J, Mamoli B. Liquorpheresis (CSF filtration) in familial amyotrophic lateral sclerosis. *Spinal Cord*. 1999;37. 518-519
- [65] Menéndez González M. Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True? *Cureus*. 2017; 520-521
- [66] Moriya M, Miyajima M, Nakajima M, et al. Impact of Cerebrospinal Fluid Shunting for Idiopathic Normal Pressure Hydrocephalus on the Amyloid Cascade. 2015; Available from: www.mhlw.go.jp. 522-523
- [67] Silverberg GD, Levinthal E, Sullivan E v., et al. Assessment of low-flow CSF drainage as a treatment for AD: Results of a randomized pilot study. *Neurology*. 2002;59. 524-525
- [68] Hadden M, Martinez-Martin D, Yong K-T, et al. Recent Advancements in the Fabrication of Functional Nanoporous Materials and Their Biomedical Applications. *Materials [Internet]*. 2022;15. Available from: <https://www.mdpi.com/1996-1944/15/6/2111>. 526-528
- [69] Kapruwan P, Ferré-Borrull J, Marsal LF. Nanoporous Anodic Alumina Platforms for Drug Delivery Applications: Recent Advances and Perspective. *Adv Mater Interfaces*. 2020. 529-530
- [70] Mabrouk M, Rajendran R, Soliman IE, et al. Nanoparticle- and nanoporous-membrane-mediated delivery of therapeutics. *Pharmaceutics*. 2019;11. 531-532
- [71] Schreiner TG, Tamba BI, Mihai CT, et al. Clinical Medicine Nanoporous Membranes for the Filtration of Proteins from Biological Fluids: Biocompatibility Tests on Cell Cultures and Suggested Applications for the Treatment of Alzheimer's Disease. *J Clin Med [Internet]*. 2022;2022:5846. Available from: <https://doi.org/10.3390/jcm11195846>. 533-535
- [72] Menendez-Gonzalez M, Vilcapoma AC, Silgado JC, et al. Intrathecal pseudodelivery of Ab-mAb alleviates pathology in an Alzheimer's disease model. *Alzheimer's & Dementia [Internet]*. 2022;18:e068697. Available from: <https://doi.org/10.1002/alz.068697>. 536-538

-
- [73] Coto-Vilcapoma MA, Castilla-Silgado J, Fernández-García B, et al. New, Fully Implantable Device for Selective Clearance of CSF-Target Molecules: Proof of Concept in a Murine Model of Alzheimer's Disease. 2022; Available from: <https://doi.org/10.3390/ijms23169256>. 539-541
- [74] Mortada I, Farah R, Nabha S, et al. Immunotherapies for Neurodegenerative Diseases. *Front Neurol*. 2021. 542
- [75] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine* [Internet]. 0:null. Available from: <https://doi.org/10.1056/NEJMoa2212948>. 543-544
- [76] Pernecky R, Jessen F, Grimmer T, et al. Anti-amyloid antibody therapies in Alzheimer's disease. *Brain* [Internet]. 2023;awad005. Available from: <https://doi.org/10.1093/brain/awad005>. 545-546
- [77] Tampi RR, Forester BP, Agronin M. Aducanumab: Evidence from clinical trial data and controversies. *Drugs Context*. 2021. 547-548
- [78] Byun J. Recent progress and opportunities for nucleic acid aptamers. *Life*. 2021. 549
- [79] Menendez-Gonzalez M, Gasparovic C. Albumin exchange in Alzheimer's disease: Might CSF be an alternative route to plasma? *Front Neurol*. 2019;10. 550-551
- [80] Loktyushov E v., Litus EA, Deryusheva EI. SYSTEMATIC SEARCH FOR PEPTIDE AND PROTEIN LIGANDS OF HUMAN SERUM ALBUMIN CAPABLE OF AFFECTING ITS INTERACTION WITH AMYLOID- β PEPTIDE. *Acta Biomed Sci*. 2022;7:19-26. 552-554
- [81] Murray KA, Hu CJ, Griner SL, et al. De novo designed protein inhibitors of amyloid aggregation and seeding. *Proceedings of the National Academy of Sciences* [Internet]. 2022;119:e2206240119. Available from: <https://doi.org/10.1073/pnas.2206240119>. 555-557
- [82] Chaudhary H, Iashchishyn IA, Romanova N v., et al. Polyoxometalates as Effective Nano-inhibitors of Amyloid Aggregation of Pro-inflammatory S100A9 Protein Involved in Neurodegenerative Diseases. *ACS Appl Mater Interfaces*. 2021;13. 558-560
- [83] Ji C, Sigurdsson EM. Current Status of Clinical Trials on Tau Immunotherapies. *Drugs*. 2021. 561
- [84] Teng E, Manser PT, Pickthorn K, et al. Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. *JAMA Neurol*. 2022;79:758-767. 562-563
- [85] Wischik CM, Harrington CR, Storey JMD. Tau-aggregation inhibitor therapy for Alzheimer's disease. *Biochem Pharmacol*. 2014. 564-565
- [86] Wischik CM, Bentham P, Gauthier S, et al. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. *J Prev Alzheimers Dis* [Internet]. 2022;9:780-790. Available from: <https://doi.org/10.14283/jpad.2022.63>. 566-569
- [87] van Lengerich B, Zhan L, Xia D, et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models. *Nat Neurosci* [Internet]. 2023; Available from: <https://doi.org/10.1038/s41593-022-01240-0>. 570-572
- [88] Ma LZ, Tan L, Bi YL, et al. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: The CABLE study. *Mol Neurodegener*. 2020;15. 573-574
- [89] Elcioğlu HK, Aslan E, Ahmad S, et al. Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model. *Mol Cell Biochem*. 2016;420. 575-576
- [90] Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. *J Neuroinflammation*. 2008;5. 577-578
- [91] Shi JQ, Shen W, Chen J, et al. Anti-TNF- α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. *Brain Res*. 2011;1368. 579-580

-
- [92] Shi JQ, Wang BR, Jiang WW, et al. Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease. *J Am Geriatr Soc*. 2011. 581
582
- [93] Ou W, Ohno Y, Yang J, et al. Efficacy and Safety of a Brain-Penetrant Biologic TNF- α Inhibitor in Aged APP/PS1 Mice. *Pharmaceutics*. 2022;14. 583
584
- [94] Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. *New England Journal of Medicine* [Internet]. 2022;387:421–432. Available from: 585
<https://doi.org/10.1056/NEJMoa2202867>. 586
587
- [95] Schenk DB, Koller M, Ness DK, et al. First-in-human assessment of PRX002, an anti- α -synuclein monoclonal antibody, in healthy volunteers. *Movement Disorders*. 2017;32. 588
589
- [96] Bluhm A, Schrepel S, von Hörsten S, et al. Proteolytic α -synuclein cleavage in health and disease. *Int J Mol Sci*. 590
2021. 591
- [97] Das S, Pukala TL, Smid SD. Exploring the structural diversity in inhibitors of α -Synuclein amyloidogenic folding, aggregation, and neurotoxicity. *Front Chem*. 2018;6. 592
593
- [98] Pons-Espinal M, Blasco-Agell L, Fernandez-Carasa I, et al. Immunosuppressive tocilizumab prevents astrocyte induced neurotoxicity in hiPSC-LRRK2 Parkinson's disease by targeting receptor interleukin-6. *bioRxiv* [Internet]. 2022;2022.08.23.504918. Available from: [http://biorxiv.org/content/early/2022/08/25/2022.08.23.504918.ab-](http://biorxiv.org/content/early/2022/08/25/2022.08.23.504918.abstract) 594
[stract](http://biorxiv.org/content/early/2022/08/25/2022.08.23.504918.abstract). 595
596
597
- [99] El-Kattan MM, Rashed LA, Shazly SR, et al. Relation of serum level of tumor necrosis factor- α to cognitive functions in patients with Parkinson's disease. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*. 598
2022;58. 599
600
- [100] Dam T, Boxer AL, Golbe LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. *Nat Med*. 2021;27. 601
602
- [101] Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. *Lancet Neurol*. 2021;20. 603
604
- [102] Soeda Y, Takashima A. New Insights Into Drug Discovery Targeting Tau Protein. *Front Mol Neurosci*. 2020. 605
- [103] Francois-Moutal L, Scott DD, Khanna M. Direct targeting of TDP-43, from small molecules to biologics: The therapeutic landscape. *RSC Chem Biol*. 2021. 606
607
- [104] Samanta N, Ruiz-Blanco YB, Fetahaj Z, et al. Superoxide Dismutase 1 Folding Stability as a Target for Molecular Tweezers in SOD1-Related Amyotrophic Lateral Sclerosis. *ChemBioChem* [Internet]. 2022;23:e202200396. Available from: <https://doi.org/10.1002/cbic.202200396>. 608
609
610
- [105] Chantadul V, Wright GSA, Ampornnanai K, et al. Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy. *Commun Biol*. 2020;3. 611
612
- [106] Pozzi S, Codron P, Soucy G, et al. Monoclonal full-length antibody against TARDNA binding protein 43 reduces related proteinopathy in neurons. *JCI Insight*. 2020;5. 613
614
- [107] Li Q, Yokoshi M, Okada H, et al. The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity. *Nat Commun*. 2015;6. 615
616
- [108] Prasad A, Bharathi V, Sivalingam V, et al. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. *Front Mol Neurosci*. 2019. 617
618
- [109] Malik R, Wiedau M. Therapeutic Approaches Targeting Protein Aggregation in Amyotrophic Lateral Sclerosis. *Front Mol Neurosci*. 2020. 619
620
- [110] Milligan C, Atassi N, Babu S, et al. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. *Muscle Nerve*. 2021;64. 621
622

-
- [111] Wood H. TNF — a potential therapeutic target for ALS. *Nat Rev Neurol* [Internet]. 2022;18:317. Available from: <https://doi.org/10.1038/s41582-022-00668-z>. 623
624
- [112] Ou W, Yang J, Simanauskaite J, et al. Biologic TNF- α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy. *J Neuroinflammation*. 2021;18. 625
626
- [113] Bartl S, Oueslati A, Southwell AL, et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington’s disease. *Neurobiol Dis*. 2020;141. 627
628
- [114] Margulis BA, Vigont V, Lazarev VF, et al. Pharmacological protein targets in polyglutamine diseases: Mutant polypeptides and their interactors. *FEBS Lett*. 2013. 629
630
- [115] Minakawa EN, Nagai Y. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases. *Front Neurosci*. 2021. 631
632
- [116] Sirbu C, Ghinescu M, Axelerad A, et al. A new era for monoclonal antibodies with applications in neurology (Review). *Exp Ther Med*. 2020;21. 633
634
- [117] Hampel H, Hardy J, Blennow K, et al. The Amyloid- β Pathway in Alzheimer’s Disease. *Mol Psychiatry*. 2021. 635
- [118] Pasięka A, Panek D, Szałaj N, et al. Dual Inhibitors of Amyloid- β and Tau Aggregation with Amyloid- β Disaggregating Properties: Extended in Cellulo, in Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer’s Agents. *ACS Chem Neurosci*. 2021;12. 636
638
- [119] Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (Tnf- α) in autoimmune disease and current tnf- α inhibitors in therapeutics. *Int J Mol Sci*. 2021. 639
640
- [120] Hu Y, Huang Z, Yang S, et al. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in behcets’ disease-associated uveitis: A systematic review and meta-analysis. *Front Pharmacol*. 2020. 641
642
- [121] Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor- α antagonists. *Drug Saf*. 2004. 643
- [122] Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, et al. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. *Neurología (English Edition)*. 2022;37. 644
645
- [123] Cabreira V, Dias L, Fernandes B, et al. Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience. *Acta Neurol Scand*. 2022. 646
647
- [124] Liu X, Li L, Wang Q, et al. A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential. *Front Immunol*. 2022;12. 648
649

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. 650
651
652
653
654